bacteri
pneumonia
substanti
caus
childhood
morbid
mortal
worldwid
determin
pathogenspecif
burden
remain
challeng
less
develop
set
recommend
guidelin
use
initi
care
nonspecif
blood
cultur
low
sensit
radiolog
find
nonspecif
discrimin
viral
bacteri
caus
pneumonia
vaccin
probe
studi
efficaci
depend
specif
studi
outcom
detect
pneumonia
impact
vaccin
select
outcom
may
underestim
true
burden
bacteri
pneumonia
rise
incid
antibiot
resist
emerg
respiratori
pathogen
potenti
replac
pneumococc
diseas
follow
widespread
introduct
pneumococc
polysaccharideprotein
conjug
vaccin
limit
specif
chest
radiographi
poor
sensit
blood
cultur
substanti
obstacl
accur
surveil
provid
overview
diagnost
challeng
bacteri
pneumonia
highlight
need
refin
current
diagnost
approach
ensur
adequ
epidemiolog
surveil
childhood
pneumonia
success
otherwis
immunis
strategi
bacteri
pneumonia
vaccin
childhood
pneumonia
win
refin
redefin
figur
nonbacteraem
lobar
pneumonia
child
posit
lung
tap
cultur
pneumonia
annual
incid
pneumonia
children
younger
year
age
case
per
europ
north
america
develop
world
incid
sever
fold
higher
although
definit
pneumonia
vari
wide
often
use
interchang
acut
lower
respiratori
tract
infect
less
develop
countri
lower
respiratori
tract
infectionsan
inclus
terminolog
pneumonia
typic
atyp
bronchiti
bronchiol
sever
acut
respiratori
syndromeremain
global
paediatr
health
problem
worldwid
million
children
die
pneumonia
annual
recent
review
child
mortal
prevent
caus
pneumonia
rank
second
respons
death
children
age
year
lowincom
countri
especi
africa
asia
death
occur
aetiolog
studi
done
larg
develop
countri
suggest
streptococcu
pneumonia
may
common
bacteri
caus
pneumonia
worldwid
figur
accur
estim
pathogenspecif
attribut
diseas
burden
elus
clinic
symptom
communityacquir
pneumonia
children
systemat
studi
children
often
brought
medic
attent
fever
difficulti
breath
without
cough
tachypnoea
accompani
crackl
auscult
suggest
diagnosi
pneumonia
although
crackl
often
heard
children
particularli
child
dehydr
wheez
often
associ
viral
mycoplasma
infect
develop
guidelin
recommend
tachypnoea
main
indic
clinic
diagnosi
lower
respiratori
infect
respiratori
rate
breathsmin
infant
breathsmin
children
year
older
although
presenc
tachypnoea
may
best
way
distinguish
lower
upper
respiratori
infect
uniform
criteria
initi
patient
workup
exampl
chest
radiograph
blood
cultur
recommend
use
develop
countri
initi
antibiot
treatment
hospitalis
howev
develop
countri
laboratori
radiolog
investig
done
gener
criteria
diagnosi
less
stringent
absenc
uniform
object
criteria
diagnosi
pneumonia
implic
determin
true
burden
childhood
pneumonia
bacteri
colonis
nasopharynx
provid
import
key
burden
sever
respiratori
pathogen
prevent
healthi
popul
host
risk
factor
affect
colonis
rate
highest
carriag
rate
toddler
attend
daycar
centr
independ
determin
nasopharyng
colonis
ethnic
environment
featur
crowd
socioeconom
statu
famili
size
incom
smoke
antibiot
use
popul
colonis
organ
divers
interact
complex
dynam
involv
differ
bacteri
speci
serotyp
competit
among
differ
bacteria
bacteria
differ
serotyp
recognis
instanc
known
alphahaemolyt
streptococci
inhibit
colonis
pneumonia
haemophilu
influenza
staphylococcu
aureu
streptococcu
pyogen
moraxella
catarrhali
pneumonia
interfer
growth
aureu
effect
attribut
pneumococc
hydrogen
peroxid
thu
advantag
colonis
result
inhibit
one
bacteri
speci
either
select
antimicrobi
inhibit
vaccin
potenti
clinic
impact
observ
yet
fulli
establish
howev
two
studi
netherland
israel
suggest
base
epidemiolog
evid
pneumonia
might
compet
aureu
colonis
use
pneumonia
model
typic
respiratori
pathogen
diseas
begin
colonis
mucos
epithelium
nasopharynx
follow
transloc
either
middl
ear
paranas
sinus
alveoli
lung
bloodstream
like
mucos
antibodi
respons
import
prevent
colonis
diseas
interestingli
serotyp
commonli
caus
invas
diseas
develop
countri
rare
detect
nasopharynx
healthi
children
carriag
studi
possibl
colonis
strain
shortliv
perhap
invas
occur
rapidli
follow
acquisit
parenter
immunis
variou
polysaccharideprotein
conjug
vaccin
elicit
serum
igg
secretori
iga
detect
saliva
infant
toddler
circul
polysaccharidespecif
igasecret
cell
detect
week
immunis
conjug
vaccin
toddler
indic
parenter
immunis
conjug
vaccin
restimul
mucos
b
memori
cell
gener
previou
pneumococc
colonis
howev
mucos
iga
respons
follow
parenter
vaccin
usual
low
detect
proport
vaccine
prevent
acquisit
new
pneumonia
vaccin
also
depend
concentr
circul
anticapsular
igg
therefor
mucos
immunis
strategi
conjug
vaccin
may
particular
advantag
enhanc
mucos
respons
improv
efficaci
mucos
infect
pneumococc
conjug
vaccin
reduc
nasopharyng
carriag
unlik
h
influenza
type
b
hib
multipl
pneumococc
serotyp
allow
complex
interact
reduct
carriag
vaccin
serotyp
associ
increas
carriag
nonvaccin
serotyp
nonvaccin
serotyp
caus
replac
diseas
middl
ear
like
caus
diseas
contigu
respiratori
mucos
surfac
follow
introduct
heptaval
conjug
vaccin
usa
least
threefold
increas
incid
nonvaccin
serotyp
invas
diseas
far
absolut
term
repres
fraction
burden
diseas
prevent
vaccin
event
increas
preval
colonis
nonvaccin
pneumococc
serotyp
among
vaccine
result
nonbacteraem
pneumonia
remain
undetect
blood
cultur
current
use
although
blood
cultur
offer
excel
opportun
aetiolog
diagnosi
bacteri
pneumonia
use
pneumonia
associ
bacteraemia
ie
bacteraem
pneumonia
nevertheless
pneumococc
bacteraemia
may
occult
sometim
innocu
sinc
clear
spontan
children
without
sequela
yield
blood
cultur
patient
pneumonia
rang
sensit
blood
cultur
diagnos
pneumonia
poor
although
benefit
may
restrict
bacteraem
pneumonia
bacteraem
nonbacteraem
pneumonia
may
inde
two
differ
clinic
entiti
current
evid
suggest
bacteraem
pneumococc
pneumonia
may
sever
diseas
nonbacteraem
pneumonia
diagnos
serolog
noteworthi
current
definit
acut
lower
respiratori
tract
infect
includ
fever
blood
cultur
seldom
done
individu
afebril
furthermor
blood
cultur
underestim
incid
pneumonia
caus
bacteria
less
like
invad
bloodstream
exampl
moraxella
osloensi
report
caus
clinic
radiolog
featur
reminisc
pneumococc
diseas
bacterium
seldom
invad
bloodstream
true
preval
ascertain
differ
diagnost
method
sinc
bacteraemia
detect
blood
cultur
constitut
import
step
pathogenesi
invas
bacteri
diseas
attract
outcom
measur
evalu
bacteri
vaccin
target
childhood
pneumonia
sensit
blood
cultur
detect
burden
pneumonia
prevent
vaccin
may
howev
low
hivuninfect
children
hivinfect
children
recent
shown
pneumococc
vaccin
efficaci
trial
south
africa
recent
studi
kenya
bacteraemia
respons
least
onethird
death
children
year
age
observ
import
implic
healthcar
intervent
region
may
fact
provid
underestim
true
burden
bacteraemia
sinc
blood
cultur
obtain
children
present
hospit
limit
blood
cultur
detect
bacteraemia
demonstr
studi
includ
loss
sensit
almost
onethird
yield
ml
blood
inoculum
compar
ml
inoculum
recent
antibiot
use
also
reduc
bacteri
yield
poor
sensit
blood
cultur
diagnosi
bacteraemia
low
incid
bacteraem
pneumonia
coupl
infrequ
practic
obtain
blood
cultur
children
pneumonia
make
unlik
prevent
bacteraem
pneumonia
would
outcom
readili
ascertain
clinician
appreci
publichealth
policymak
studi
gambia
evalu
clinic
sign
predict
posit
blood
cultur
children
present
pneumonia
high
temperatur
c
dehydr
nasal
flare
grunt
bronchial
breath
sound
diminish
air
entri
posit
predictor
posit
blood
cultur
pattern
posit
neg
predictor
cultur
pneumonia
differ
seen
posit
blood
cultur
overal
clinic
sign
pneumonia
stronger
posit
predictor
cultur
pneumonia
cultur
bacteria
posit
chest
radiograph
pneumonia
also
posit
predictor
although
report
provid
descript
detail
posit
chest
radiograph
suggest
possibl
select
individu
like
posit
blood
cultur
base
sever
clinic
paramet
efficaci
trial
bacteri
conjug
vaccin
date
report
efficaci
bacteraemia
andor
mening
common
manifest
invas
bacteri
diseas
follow
licensur
hib
conjug
vaccin
remark
success
control
invas
hib
diseas
pneumococc
conjug
vaccin
develop
use
similar
technolog
first
efficaci
trial
done
usa
vaccin
licens
februari
klugman
colleagu
ad
optim
global
control
invas
pneumococc
diseas
children
addit
show
efficaci
invas
pneumococc
diseas
hivuninfect
children
vaccin
also
reduc
invas
pneumococc
diseas
ci
hivinfect
children
find
import
sinc
hivinfect
children
constitut
group
greater
risk
develop
invas
pneumococc
diseas
hivuninfect
children
contribut
twothird
bacteraem
pneumococc
case
children
subsaharan
african
countri
recent
gambia
nonaval
pneumococc
conjug
vaccin
evalu
south
africa
demonstr
efficaci
vaccin
serotyp
ci
associ
increas
diseas
caus
nonvaccin
serotyp
howev
absolut
reduct
invas
pneumococc
diseas
per
childyear
due
prevent
diseas
vaccin
serotyp
compar
increas
case
invas
pneumococc
diseas
due
nonvaccin
serotyp
henc
net
prevent
episod
invas
pneumococc
diseas
per
childyear
similar
increas
incid
diseas
caus
nonvaccin
serotyp
observ
hivuninfect
children
south
africa
increas
invas
pneumococc
diseas
due
nonvaccin
serotyp
diseas
observ
whether
distribut
pneumococc
serotyp
caus
bacteraem
pneumonia
differ
substanti
caus
nonbacteraem
pneumonia
known
howev
incid
nonbacteraem
pneumonia
caus
nonvaccin
serotyp
increas
case
otiti
media
current
diagnost
method
would
inadequ
detect
chang
diagnost
lung
tap
procedur
describ
centuri
ago
may
provid
valuabl
inform
aetiolog
nonbacteraem
pneumonia
sinc
origin
descript
procedur
undergon
sever
modif
mani
respect
similar
spinal
tap
safer
gener
believ
involv
gener
anaesthesia
bronchoalveolar
lavag
furthermor
pneumothorax
result
lung
tap
asymptomat
case
resolv
spontan
recent
review
studi
bacteri
aetiolog
diagnosi
obtain
lung
tap
case
aetiolog
studi
pneumonia
lung
aspir
done
suggest
aetiolog
pneumonia
sometim
polymicrobi
bacteri
isol
obtain
blood
cultur
may
discrep
isol
obtain
lung
pleural
aspir
studi
aetiolog
pneumonia
children
gambia
children
investig
blood
cultur
cultur
lung
pleural
aspir
children
one
speci
bacterium
isol
blood
six
case
lung
cultur
case
eight
case
eight
children
two
speci
isol
lung
pleural
aspir
thu
indic
blood
cultur
isol
may
alway
reflect
offend
pathogen
lung
group
children
lobar
pneumonia
empyema
blood
cultur
alon
yield
bacteri
pathogen
case
addit
percutan
lung
aspir
pleural
aspir
increas
yield
case
studi
lung
aspir
convent
bacteri
cultur
techniqu
done
determin
aetiolog
pneumonia
although
techniqu
reveal
yield
may
consider
enhanc
molecular
method
nucleic
acid
amplif
techniqu
addit
sinc
aspir
done
lung
consolid
adjac
chest
wall
true
burden
pneumonia
prevent
vaccin
use
lung
aspir
underestim
alveolar
consolid
chest
radiograph
may
detect
pneumonia
otherwis
prevent
vaccin
data
lung
aspir
studi
need
interpret
within
context
limit
appreci
although
lung
aspir
provid
substanti
inform
regard
aetiolog
pneumonia
compar
blood
cultur
provid
complet
data
true
burden
nonbacteraem
pneumonia
type
pneumonia
access
lung
aspir
may
repres
spectrum
pneumonia
case
present
clinic
report
data
lung
aspir
limit
pneumonia
present
larg
dens
peripher
consolid
predominantli
right
thu
data
lung
aspir
studi
assum
appli
aetiolog
distribut
pneumonia
central
interstiti
infiltr
data
lung
aspir
studi
date
also
limit
bacteri
isol
type
radiolog
find
commonli
accept
gold
standard
defin
pneumonia
although
differ
definit
formal
valid
addit
consider
interobserv
intraobserv
variabl
interpret
chest
film
report
valu
routin
chest
radiograph
uncompl
clinic
pneumonia
controversi
nevertheless
obtain
chest
radiograph
suspect
case
pneumonia
virtual
standard
practic
affluent
countri
broad
spectrum
overlap
radiolog
find
observ
viral
bacteri
pneumonia
although
confluent
opac
alveolar
infiltr
wide
attribut
bacteri
origin
sever
studi
attempt
standardis
interpret
chest
radiograph
childhood
pneumonia
first
report
radiolog
find
bacteri
pneumonia
vaccin
trial
children
gambia
studi
hib
conjug
vaccin
efficaci
clinic
pneumonia
radiolog
pneumonia
efficaci
hib
pneumonia
confirm
lung
tap
observ
gener
lot
interest
bacteri
pneumonia
vaccin
studi
plan
standardis
chest
radiograph
vaccin
efficaci
studi
pursu
effort
standardis
interpret
chest
radiograph
specif
purpos
evalu
impact
vaccin
pneumonia
initi
group
paediatrician
radiologist
set
develop
consensu
briefli
interobserv
variabl
categoris
chest
radiograph
imag
measur
compar
read
radiologist
clinician
refer
set
radiograph
film
intraobserv
variabl
measur
compar
initi
read
randomli
chosen
subset
radiograph
repeat
read
made
week
later
standardis
definit
improv
agreement
substanti
among
member
group
identif
radiolog
pneumonia
although
report
provid
valuabl
guidelin
excel
tool
evalu
radiolog
pneumonia
outcom
measur
paediatr
bacteri
pneumonia
vaccin
efficaci
trial
epidemiolog
studi
unansw
question
remain
definit
alveolar
consolid
propos
group
need
formal
evalu
establish
correl
bacteri
pneumonia
radiolog
pneumonia
propos
group
unlik
use
clinic
set
radiograph
evalu
context
clinic
present
indic
obtain
chest
radiograph
vari
consider
metaanalysi
data
two
randomis
control
trial
pneumococc
conjug
vaccin
done
usa
south
africa
suggest
pneumococc
conjug
vaccin
reduc
incid
radiolog
pneumonia
ci
recent
find
gambia
countri
much
less
develop
less
access
antibiot
outsid
studi
centr
compar
south
africa
usa
show
reduct
radiolog
pneumonia
ci
differ
case
ascertain
clinic
practic
time
onset
symptom
present
healthcar
facil
may
part
explain
differ
point
estim
efficaci
radiolog
pneumonia
tabl
report
california
treat
physician
made
clinic
diagnosi
pneumonia
base
individu
apprais
physic
examin
need
chest
radiograph
base
physician
assess
radiologist
interpret
radiograph
thu
introduc
consider
potenti
interobserv
variabl
studi
south
africa
gambia
use
standard
recommend
trialist
group
interpret
chest
radiograph
howev
clinic
indic
obtain
chest
radiograph
south
african
studi
base
individu
studyphysician
assess
standardis
case
reduct
lower
respiratori
tract
infect
episod
use
benchmark
measur
sensit
standardis
studi
endpoint
radiolog
pneumonia
prevent
vaccin
south
african
hivuninfect
children
chest
radiographi
detect
ci
pneumococc
pneumonia
prevent
vaccin
gambia
sensit
chest
radiographconfirm
pneumonia
detect
burden
pneumonia
prevent
vaccin
ci
import
modifi
current
clinic
definit
lower
respiratori
tract
infect
improv
specif
pneumococc
pneumonia
corrobor
find
south
africa
analysi
exclus
children
wheez
absenc
chest
radiographconfirm
pneumonia
provid
sensit
measur
vaccineprevent
pneumonia
use
refin
definit
clinic
pneumonia
sensit
chest
radiographconfirm
pneumonia
diagnos
burden
pneumococc
pneumonia
prevent
vaccin
ci
despit
differ
radiolog
pneumonia
gambia
compar
observ
south
africa
usa
overal
reduct
lower
respiratori
tract
infect
similar
studi
furthermor
although
efficaci
radiolog
pneumonia
ci
ci
hivuninfect
hivinfect
children
respect
south
africa
case
reduct
burden
pneumococc
pneumonia
prevent
hivinfect
children
case
per
personyear
ci
fold
greater
hivuninfect
children
case
per
childyear
chile
hib
conjug
vaccin
reduc
substanti
incid
nonbacteraem
pneumonia
particularli
case
alveolar
consolid
andor
pleural
effus
howev
clusterrandomis
efficaci
trial
hib
conjug
vaccin
lombok
indonesia
show
vaccin
prevent
pneumonia
case
includ
alveolar
consolid
vaccin
efficaci
use
guidelin
chest
radiograph
interpret
despit
absolut
burden
clinic
diagnos
lower
respiratori
tract
infect
reduc
case
per
childyear
compar
reduct
per
childyear
gambia
studi
although
differ
case
ascertain
studi
allow
direct
comparison
made
nevertheless
lower
proport
reduct
chest
radiographconfirm
pneumonia
indonesia
may
reflect
predomin
pneumonia
caus
bacteria
popul
possibl
explan
differ
result
indonesia
compar
studi
may
includ
differ
case
ascertain
local
clinic
practic
may
impact
specif
chest
radiograph
use
surrog
marker
bacteri
pneumonia
evalu
vaccin
efficaci
also
two
casecontrol
studi
done
brazil
colombia
evalu
effect
hib
conjug
vaccin
prevent
chest
radiographconfirm
pneumonia
point
estim
reduct
radiographconfirm
pneumonia
studi
especi
colombia
vaccin
effect
ci
greater
report
gambia
chile
howev
inher
problem
casecontrol
studi
includ
fact
unvaccin
children
may
medic
socioeconom
factor
may
predispos
develop
pneumonia
would
bia
estim
vaccin
effect
pneumonia
upward
addit
differ
surveil
system
criteria
use
initi
investig
pneumonia
may
also
affect
specif
chest
radiograph
individu
studi
diagnos
bacteri
pneumonia
would
also
bias
measur
effect
upward
exampl
studi
colombia
chest
radiograph
done
children
clinic
laboratori
suspicion
bacteri
pneumonia
compar
gambian
studi
children
refer
health
centr
clinic
symptom
lower
respiratori
tract
infect
chest
radiograph
indonesia
studi
activ
surveil
lower
respiratori
tract
infect
outcom
case
children
clinic
diagnosi
lower
respiratori
tract
infect
chest
radiograph
done
differ
studi
design
case
ascertain
procedur
use
interpret
chest
radiograph
make
direct
comparison
result
studi
evalu
use
hib
conjug
vaccin
problemat
nevertheless
publichealth
import
studi
includ
indonesia
confirm
hib
conjug
vaccin
reduc
childhood
morbid
associ
pneumonia
detail
report
efficaci
trial
pneumococc
conjug
vaccin
hib
conjug
vaccin
trial
differ
site
outcom
summaris
tabl
tabl
respect
variou
serolog
test
avail
evalu
acut
lower
respiratori
tract
infect
children
specif
test
panel
test
consist
use
differenti
viral
bacteri
pneumonia
identif
marker
infect
discrimin
bacteri
viral
pneumonia
would
enorm
potenti
reduc
cost
unnecessari
antibiot
prescript
peripher
leucocytosi
andor
rais
erythrocyt
sediment
rate
corrobor
bacteri
pneumonia
neither
reliabl
differenti
viral
bacteri
pneumonia
similarli
creactiv
protein
crp
procalcitonin
interleukin
level
rais
bacteri
pneumonia
reliabl
cutoff
level
defin
clinic
use
consider
overlap
valu
made
interpret
level
difficult
hypothesesgener
studi
data
pneumococc
conjug
vaccin
trial
suggest
crp
concentr
least
mgl
procalcitonin
least
ngml
adjunct
marker
pneumococc
pneumonia
substanti
improv
specif
chest
radiographi
diagnosi
pneumococc
pneumonia
howev
improv
specif
achiev
sacrif
sensit
ci
outcom
detect
absolut
burden
pneumococc
pneumonia
prevent
vaccin
although
combin
acut
phase
reactant
radiolog
diagnosi
promis
valu
warrant
evalu
prospect
trial
combin
may
use
minimis
sampl
size
requir
evalu
vaccin
efficaci
ie
improv
specif
studi
outcom
measur
howev
poor
sensit
would
preclud
use
measur
absolut
burden
diseas
prevent
vaccin
definit
marker
use
distinguish
bacteri
viral
pneumonia
handicap
poor
sensit
current
avail
tool
diagnos
bacteri
pneumonia
recent
corrobor
use
pneumococc
conjug
vaccin
probe
defin
minim
contribut
pneumococc
coinfect
children
hospitalis
viralassoci
pneumonia
determin
sensit
blood
cultur
diagnos
pneumococc
pneumonia
absenc
immunis
pneumococc
conjug
vaccin
least
hospitalis
viralassoci
pneumonia
attribut
pneumococc
coinfect
albeit
differ
preval
pneumococc
bacteraemia
vaccin
placebo
recipi
studi
children
attend
daycar
centr
israel
reduct
incid
presum
viral
lower
respiratori
tract
infect
reduct
antibiot
use
lower
respiratori
tract
infect
concept
use
vaccin
defin
burden
vaccineprevent
diseas
commun
base
concept
excess
riski
risk
differencea
standard
paramet
studi
exposur
ill
approach
use
previous
influenza
vaccin
evalu
vaccineprevent
ill
among
pilgrim
travel
hajj
pakistan
difficulti
associ
establish
pathogenspecif
burden
pneumonia
lack
reproduc
quantit
measur
pathogenattribut
risk
make
difficult
justifi
use
conjug
vaccin
mani
set
howev
littl
doubt
bacteri
polysaccharideprotein
conjug
vaccin
made
substanti
impact
battl
invas
bacteri
diseas
childhood
date
frustrat
associ
lack
refin
clinic
laboratori
diagnost
tool
quantit
defin
reduct
diseas
burden
prompt
investig
use
vaccin
probe
defin
diseas
burden
advantag
shortcom
use
vaccin
probe
approach
determin
diseas
burden
subject
recent
review
although
approach
provid
power
tool
evalu
vaccin
efficaci
diseas
diseas
reduct
would
proport
vaccin
efficaci
studyspecifi
outcom
measur
appropri
refer
vaccineprevent
diseas
proport
diseas
prevent
vaccin
equal
diseas
burden
vaccin
efficaci
sinc
vaccin
exist
licens
vaccin
efficaci
vari
differ
popul
use
approach
defin
diseas
burden
underestim
true
diseas
burden
although
strategi
provid
power
unequivoc
tool
evalu
reduct
allcaus
morbid
mortal
demonstr
gambia
true
burden
pneumococc
pneumonia
remain
undetermin
vaccin
impact
form
diseas
addit
pneumonia
although
efficaci
protein
conjug
bacteri
polysaccharid
vaccin
high
prevent
bacteraemia
mening
less
otiti
media
pneumonia
sinc
known
degre
infiltr
chest
radiograph
correl
clinic
sever
radiolog
present
bacteri
pneumonia
like
continuum
reduct
alveolar
consolid
observ
sever
efficaci
studi
like
repres
fraction
total
burden
pneumococc
pneumonia
addit
data
impact
vaccin
pneumococc
pneumonia
diagnos
lung
tap
would
certainli
inform
although
would
somewhat
limit
sinc
procedur
done
select
case
estim
million
children
die
annual
worldwid
million
death
occur
within
first
day
life
use
current
neonat
mortal
estim
limit
autopsi
data
report
literatur
recent
review
suggest
pneumonia
may
respons
million
death
unknown
number
stillbirth
year
worldwid
greatest
risk
death
pneumonia
like
occur
neonat
period
least
develop
countri
india
half
child
death
pneumonia
occur
neonat
aetiolog
epidemiolog
neonat
pneumonia
complex
infanc
childhood
aetiolog
spectrum
divers
gener
earli
onset
diseas
onset
within
first
week
life
occur
bacteri
infect
amniot
fluid
colonis
matern
genit
tract
gramneg
bacteria
predomin
pathogen
first
week
life
gramposit
bacteria
thereaft
intrauterin
pneumonia
compon
earli
onset
diseas
may
result
stillbirth
conflict
report
incid
neonat
group
b
streptococc
infect
develop
develop
countri
studi
aetiolog
seriou
bacteri
infect
young
infant
sever
develop
countri
suggest
group
b
streptococcu
uncommon
studi
recruit
infant
outpati
set
would
miss
substanti
burden
earli
onset
diseas
report
contrast
recent
observ
kenya
clinic
aetiolog
diagnosi
even
challeng
sinc
neonat
pneumonia
often
present
neonat
sepsi
sign
illdefin
clinic
distinct
earli
onset
pneumonia
hyalin
membran
diseas
virtual
imposs
similar
radiolog
find
condit
blood
cultur
yield
like
lower
given
smaller
volum
blood
specimen
often
avail
cultur
one
studi
brazil
neonat
present
respiratori
distress
within
first
hour
life
bacteri
infect
proven
cultur
radiograph
chang
suggest
pneumonia
aetiolog
studi
neonat
pneumonia
use
lung
tap
diagnosi
two
studi
india
report
bacteri
cultur
bacteri
antigen
studi
lung
aspir
suggest
escherichia
coli
pneumonia
import
caus
neonat
pneumonia
modifi
definit
sensit
diagnos
bacteri
pneumoniai
consolid
effus
bronchial
breath
esr
mmhvaccin
efficaci
calcul
ci
incid
rate
childyear
control
group
var
per
childyear
importantli
children
mix
interstitialalveolar
consolid
exclud
outcom
case
radiolog
confirm
pneumonia
contrast
studi
gambia
indonesia
although
substanti
progress
made
develop
polysaccharideprotein
conjug
vaccin
common
bacteri
pathogen
acut
respiratori
infect
pathogen
vaccin
use
similar
technolog
either
develop
earli
clinic
trialseg
group
b
streptococcu
sever
diseas
substanti
pathogenspecif
burden
earli
infanc
eg
group
b
streptococc
diseas
pneumococc
diseas
may
possibl
offer
protect
newborn
infant
could
last
first
month
life
offer
vaccin
mother
pregnanc
sever
studi
demonstr
safeti
immunogen
polyval
pneumococc
polysaccharid
vaccin
administ
second
third
trimest
pregnanc
recent
conjug
group
b
streptococc
vaccin
immunis
pneumococc
polysaccharid
vaccin
shown
safe
immunogen
administ
late
pregnanc
function
serotypespecif
antibodi
detect
breast
milk
sever
month
deliveri
provid
efficaci
demonstr
immunis
mother
pregnanc
could
offer
potenti
benefit
protect
pneumococc
diseas
mother
infant
protect
pneumococc
serotyp
current
avail
licens
heptaval
pneumococc
conjug
vaccin
first
sever
month
life
addit
infant
may
possibl
achiev
adequ
immun
protect
use
fewer
dose
conjug
vaccin
later
infanc
overal
given
complex
pathogenesi
broad
spectrum
aetiolog
agent
control
neonat
pneumonia
would
involv
gener
support
healthcar
intervent
addit
immunis
women
pregnanc
substanti
progress
made
control
bacteri
pneumonia
develop
bacteri
polysaccharideprotein
conjug
vaccin
two
major
respiratori
pathogen
childhood
pneumonia
hib
pneumonia
vaccin
pneumonia
caus
pathogen
well
control
sever
mostli
develop
countri
use
either
vaccin
becom
routin
howev
vaccin
remain
reach
children
develop
countri
substanti
global
burden
diseas
morbid
mortal
occur
although
global
allianc
vaccin
initi
instrument
make
hib
conjug
vaccin
avail
develop
countri
lack
pathogenspecif
pneumonia
burden
data
remain
major
obstacl
convinc
health
polici
planner
polit
leader
need
vaccin
develop
countri
even
affluent
countri
perceiv
burden
diseas
provid
econom
justif
routin
use
vaccin
although
vaccin
probe
studi
inform
expens
experiment
best
provid
estim
vaccineprevent
studyspecifi
diseas
outcom
develop
better
tool
determin
microbiolog
diagnosi
pneumonia
critic
demonstr
diseas
burden
tool
vital
indic
need
vaccin
monitor
epidemiolog
pneumonia
thereaft
true
burden
pneumonia
remain
unknown
diagnost
difficulti
vaccin
provid
minimum
attribut
rate
reduct
although
data
may
incomplet
diagnost
imprecis
challeng
data
complet
suffici
initi
publichealth
decis
author
particip
evalu
safeti
immunogen
efficaci
trial
haemophilu
influenza
type
b
pneumococc
conjug
vaccin
sponsor
least
part
wyeth
vaccin
pediatr
sanofiaventi
author
also
act
consult
wyeth
addit
sam
salari
support
research
grant
fund
wyeth
vaccin
pediatr
phase
studi
pneumococc
conjug
vaccin
temporari
advisor
glaxosmithklin
sanofiaventi
data
review
identifi
search
pubm
articl
identifi
search
file
author
pubm
search
term
pneumococc
conjug
vaccin
radiolog
pneumonia
bacteri
conjug
vaccin
radiograph
pneumonia
child
diagnosi
search
restrict
articl
publish
english
languag
articl
select
basi
relev
evalu
pneumonia
children
search
refer
list
exist
articl
identifi
addit
articl
